Efficacy and tolerability of valsartan compared with lisinopril in patients with hypertension and renal insufficiency

Clinical Drug Investigation

Volumn 14, Issue 4, 1997, Pages 252-259

  Perico, N ^a   Spormann, D ^b   Peruzzi, E ^c   Bodin, F ^b   Sioufi, Antoine ^d   Bertocchi, F ^c  

^a MARIO NEGRI INST PHARMACOL RES   (Italy)

^b NOVARTIS PHARMA AG   (Switzerland)

^c Novartis SpA   (Italy)

^d Novartis   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRUG; FUROSEMIDE; IMMUNOGLOBULIN G; LISINOPRIL; VALSARTAN;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CREATININE CLEARANCE; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE;

EID: 0030668490     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199714040-00002     Document Type: Article

References (24)

1. Kaplan NM. Clinical hypertension. Baltimore: Williams and Wilkins, 1994; 118
2. Mimran A. Renal effects of antihypertensive agents in parenchymal renal disease and renovascular hypertension. J Cardiovasc Pharmacol 1992; 19: S45-S50
3. Mogensen CE. Long term antihypertensive treatment inhibiting progression of diabetic nephropathy. BMJ 1982; 285: 685-8
4. Parving HH, Andersen AR, Smidt UM, et al. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1983; I: 1176-8
5. Parving HH, Hommel E, Smidt UM. Protection of kidney function and decrease in albuminuria by captopril in insulin dependent diabetics with nephropathy. BMJ 1988; 297: 1086-91
6. Romero C, Raij L, Granger JP, et al. Multiple effects of calcium entry blockers on renal function in hypertension. Hypertension 1987; 10: 140-51
7. Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996; 334: 939-45
8. Lewis EJ, Hunziker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy [published erratum appears in N Engl J Med 1993; 330: 152]. N Engl J Med 1993; 329: 1456-62
9. Perna A, Remuzzi G. Abnormal permeability to proteins and glomerular lesions: a meta-analysis of experimental and human studies. Am J Kidney Dis 1996; 27: 34-41
10. Johnston CI. Angiotensin receptor antagonists: focus on losartan. Lancet 1995; 346: 1403-7
11. Gansevoort RT, de Zeeuw D, Shahinfar S, et al. Effect of the angiotensin II antagonist losartan in hypertensive patients with renal disease. J Hypertens 1994; 12: S37-S42
12. Gansevoort RT, de Zeeuw D, de Jong PE. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidney Int 1994; 45: 861-7
13. Müller P, Cohen T, de Gasparo M, et al. Angiotensin II receptor blockade with single doses of valsartan in healthy, normotensive subjects. Eur J Clin Pharmacol 1994; 47: 231-45
14. Markham A, Goa KL. Valsartan: a review of its pharmacology and therapeutic use in essential hypertension. Drugs 1997 Aug; 54 (2): 299-311
15. Corea L, Cardoni O, Fogari R, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine. Clin Pharm Ther 1996; 60: 341-6
16. Oparil S, Dyke S, Harris F, et al. The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension. Clin Ther 1996; 18 (5): 797-810
17. Holwerda NJ, Fogari R, Angeli P, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared to placebo and enalapril. J Hypertens 1996; 14: 1147-51
18. Hegner G, Faust G, Freytag F, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared to hydrochlorothiazide. Eur J Clin Pharmacol 1997; 52: 173-7
19. Guidelines for the management of mild hypertension: memorandum from WHO/ISH meeting. Clin Exp Hypertens 1993; 15 (6): 1363-95
20. Gaspari F, Perico N, Ruggenenti P, et al. Plasma clearance of nonradioactive iohexol as a measure of glomerular filtration rate. J Am Soc Nephrol 1995; 6: 257-63
21. Lipsitz L. Orthostatic hypotension in the elderly. N Engl J Med 1989; 321: 952-7
22. Tikkanen I, Omvik P, Jensen HA. Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension. J Hypertens 1995; 13: 1343-51
23. Burnier M, Pechere-Bertschi A, Nussberger J, et al. Studies of the renal effects of angiotensin II receptor blockade: the confounding factor of acute water loading on the action of vasoactive systems. Am J Kidney Dis 1995; 26: 108-15
24. Müller P, Flesch G, de Gasparo M, et al. Single and multiple dose Phase I trials with the angiotensin II antagonist valsartan. J Hypertens 1993; 11: S459